logo BDSP

Base documentaire

  1. Cardiovascular mortality in growth hormone-deficient adults.

    Article, Communication - En anglais

    Novo Nordisk hGH Symposium. Lyon, FRA, 1998/04/23.

    It is well known that patients with hypopituitarism have increased mortality.

    Because growth hormone (GH) is not substituted, in contrast with other pituitary hormones, GH deficiency might be the underlying cause.

    There is, however, some debate as to whether cardiovascular mortality is also increased.

    We reviewed the results of the three published studies on mortality in these patients.

    The studies were conducted in patients with hypopituitarism diagnosed between 1946 and 1993.

    Survival since diagnosis and cause of death were retrieved and compared with the mortality of the general population.

    Follow-up ranged from 1 to 40 years.

    The total number of deaths was 104,50 and 188, whereas the number of cardiovascular deaths was 60,21 and 80, respectively.

    All results were statistically significant (p<0.01), except cardiovascular mortality in the UK study (p=0.11).

    The associations remained statistically significant after adjustment for age, gender, duration of disease, number of axes involved, and history of radiotherapy.

    Earlier age of onset was associated with higher mortality in one study, whereas hypogonadal patients showed better survival in another study.

    The ratios of observed over expected deaths were quite similar in the three studies, whereas the 95% confidence intervals overlapped.

    The most likely explanation for the non-statistically increased cardiovascular mortality in the UK study is therefore the small sample size. (...)

    Mots-clés Pascal : Insuffisance hypophysaire, STH, Déficit, Appareil circulatoire pathologie, Mortalité, Epidémiologie, Facteur risque, Pays Bas, Europe, Homme, Endocrinopathie, Hypophyse pathologie

    Mots-clés Pascal anglais : Hypophyseal insufficiency, Somatotropin hormone, Deficiency, Cardiovascular disease, Mortality, Epidemiology, Risk factor, Netherlands, Europe, Human, Endocrinopathy, Pituitary diseases

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 99-0038325

    Code Inist : 002B30A01A2. Création : 31/05/1999.